Derniers articles

Could 18-FDG PET-CT Radiomic Features Predict the Locoregional Progression-Free Survival in Inoperable or Unresectable Oesophageal Cancer?

AbstractBackground: We evaluated the value of pre-treatment positron-emission tomography-computed tomography...

Posté par : Mme. Julie HENRIQUES, Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Nom de la revue : Cancers (Basel)

Correlation between efficacy endpoints in patients with advanced biliary tract cancer treated by systemic second-line therapies: Analysis of aggregated data from a systematic literature review

AbstractBackground: Overall response rate (ORR) and progression-free survival (PFS) are commonly used as endpoints...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Clin Res Hepatol Gastroenterol

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study

AbstractPurpose: In patients with resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma, surgery plus...

Posté par : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Nom de la revue : Journal of Clinical Oncology

A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 T H 1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study

AbstractBackground: There is a strong rational of using anti-programmed cell death protein-1 and its ligand...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Front Oncol

Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study

AbstractPurpose: This prospective pharmacokinetic (PK) ancillary study of the TEXCAN phase II GERCOR trial of...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : European journal of cancer

Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study"

AbstractIntroduction: Regorafenib (R) and trifluridine/tipiracil (FTD/TPI) are of proven efficacy in metastatic...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Clinical colorectal cancer

Early Post-Transplant Red Blood Cell Transfusion Is Associated With an Increased Risk of Transplant Failure: A Nationwide French Study

AbstractBackground: Red blood cell (RBC) transfusions are frequently required in the early period after kidney...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Frontiers in oncology

Prognostic value of CD4+ T lymphopenia in non-small cell lung Cancer

AbstractBackground: There is a paucity of data regarding the prognostic influence of peripheral blood CD4+ T...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : BMC cancer

Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR)

AbstractBackground: Histological characteristics at the invasive front may reflect tumor aggressiveness;...

Posté par : Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Nom de la revue : Annals of oncology

Result of one-year, prospective follow-up of intensive care unit survivors after SARS-CoV-2 pneumonia

AbstractIntroduction: Survivors of viral ARDS are at risk of long-term physical, functional and neuropsychological...

Posté par : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY
Nom de la revue : Annals of Intensive Care

Interest of the Addition of Taxanes to Standard Treatment in First-Line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients

AbstractBackground: Studies have reported a beneficial role of the addition of trastuzumab to platin-5-FU based...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Frontiers in oncology

Is it safe to perform an anastomosis for rectal cancer after prostate cancer? A multicentre study of 126 patients from the GRECCAR group

AbstractAim: To determine the safety of performing an anastomosis after rectal cancer (RC) resection in patients...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Colorectal Dis

Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies

AbstractBackground: Squamous cell carcinoma of the anus (SCCA) is a rare disease often diagnosed at a localised...

Posté par : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Eur J Cancer

Immune microenvironment in patients with mismatch-repair-proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study

AbstractIn the era of immune checkpoint inhibitors, understanding the metastatic microenvironment of proficient mismatch...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Mol Oncol

Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin

AbstractPurpose: Early-onset (EO) colorectal cancer (CRC, age < 50 years) incidence is increasing. Decisions on...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : J Clin Oncol

Impact of Immunoscore on the Management of Stage II Colon Cancer Patients: A Physician Survey

AbstractBackground: Adjuvant chemotherapy use in stage II colon cancer is controversial. Current prognostic risk...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Cancers (Basel)

HPV16 Load Is a Potential Biomarker to Predict Risk of High-Grade Cervical Lesions in High-Risk HPV-Infected Women: A Large Longitudinal French Hospital-Based Cohort Study

AbstractHigh-risk HPV (hrHPV) testing has been implemented as a primary screening tool for cervical cancer in numerous...

Posté par : Mme. Julie HENRIQUES, Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY
Nom de la revue : Cancers (Basel)

Metastatic colorectal carcinoma with signet-ring cells: Clinical, histological and molecular description from an Association des Gastro-Entérologues Oncologues (AGEO) French multicenter retrospective cohort

AbstractBackground: Metastatic signet-ring cell colorectal carcinoma is rare. We analyzed its clinicopathological...

Posté par : , Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Dig Liver Dis

Prognostic value and relation with adjuvant treatment duration of ctDNA in stage III colon cancer: a post-hoc analysis of the PRODIGE-GERCOR IDEA-France trial

AbstractPurpose: Circulating tumor DNA (ctDNA) has been suggested as a major prognostic factor in resected stage...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Clin Cancer Res .

Additive Value of Preoperative Sarcopenia and Lymphopenia for Prognosis Prediction in Localized Pancreatic Ductal Adenocarcinoma

AbstractBackground: Surgical resection with adjuvant chemotherapy is the only treatment that can provide long term...

Posté par : Dr. Dewi VERNEREY, ,
Nom de la revue : Front Oncol